IP51/3 – Minimally invasive radical hysterectomy for early stage cervical cancer guidance
30 March 2020
Due to the operational challenges that the COVID-19 pandemic is posing to the NICE normal work programmes, NICE has announced that it is currently reviewing all guidance in development and will only be prioritising therapeutically-critical topics, or those relating to diagnosing or treating COVID-19. IP51/3 – Minimally invasive radical hysterectomy for early stage cervical cancer guidance is now on hold.
For more information click here